Table 1. Patient demographics and baseline characteristics.

Characteristics of all included patients	N (%)
Sex  Male  Female	24 (77%) 7 (23%)
Initial location of the tumor  Oral cavity  Oropharynx  Hypopharynx  Larynx	10 (32%) 14 (45%) 4 (13%) 3 (10%)
Stage at the initial diagnosis  I  II  III  Iva  IVb  IVc  Unknown	2 (6%) 3 (10%) 6 (19%) 14 (45%) 3 (10%) 2 (6%) 1 (3%)
Initial curative treatment (all but IVc patients)  Surgery then Radiotherapy  Chemoradiotherapy  Surgery then Chemoradiotherapy	7 (24%) 14 (48%) 8 (28%)
Chemotherapies for recurrent/metastatic disease First line  Platin-Taxane-Cetuximab  Platin-Taxane  Platin-5FU  Platin-Taxane-5FU  Platin-Cetuximab  Platin-5FU-Cetuximab  Taxane Second line  Cetuximab (or other anti-EGFR)  Taxane-Cetuximab  Methotrexate  Platin-Taxane  Platin-5FU-Cetuximab  Platin-Taxane-Cetuximab  Taxane  Capecitabine  Etoposide Third line  Capecitabine  Platin-Taxane  Cetuximab  Platin-Cetuximab  Taxane  Gemcitabine  Clinical Trial Fourth line  Methotrexate  Platin-Cetuximab  Taxane  Capecitabine  Vinorelbine Fifth line  Methotrexate  Taxane	31 patients 10 (32%) 7 (23%) 4 (13%) 4 (13%) 3 (10%) 2 (6%) 1 (3%) 29 patients (94%) 10 (35%) 6 (21%) 5 (17%) 3 (10%) 1 (3%) 1 (3%) 1 (3%) 1 (3%) 1 (3%) 13 patients (42%) 5 (38%) 2 (15%) 2 (15%) 1 (8%) 1 (8%) 1 (8%) 1 (8%) 8 patients (26%) 3 (38%) 2 (25%) 1 (12%) 1 (12%) 1 (12%) 2 patients (6%) 1 (50%) 1 (50%)
Disease at the onset of Cabazitaxel  Locoregional recurrence only  Locoregional recurrence with metastases  Metastases only	9 (29%) 13 (42%) 9 (29%)
Age at the onset of Cabazitaxel	Median 60 years [30–71]
Performance status at the onset of Cabazitaxel  0  1  2	4 (13%) 19 (61%) 8 (26%)